Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 19

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 19
---
 ​ | Operating expense | ​ |                                          0.78 | ​ |   0.77 | ​ |      2 | ​ |   0.74 | ​ |      6 | ​ |                    -68 |   |            124 |
| SEK      | ​ | Operating expense | ​ |                                         10.57 | ​ |  10.17 | ​ |      4 | ​ |   9.56 | ​ |     11 | ​ |                     -9 |   |             69 |
| Other    |   | ​                 | ​ |                                             ​ | ​ |      ​ | ​ |      ​ | ​ |      ​ | ​ |      ​ | ​ |                   -557 | ​ |           -289 |

| 1. | Assumes the average exchange rate vs USD in FY 2025 is 5% lower than the average rate in FY 2024. The impact data are estimates, based on best prevailing assumptions around currency profiles. |

| 2. | Based on average daily spot rates 1 January 2024 to 31 December 2024. |

| 3. | Based on average daily spot rates 1 January 2025 to 30 June 2025. |

| 4. | Based on average daily spot rates 1 June 2025 to 30 June 2025. |

Related-party transactions There have been no significant related-party transactions in the period. Principal risks and uncertainties The Principal Risks and uncertainties facing the Group are set out on pages 65 to 66 of the Annual Report and Form 20-F Information 2024 and summarised below. They are not expected to change in respect of the second six months of the financial year and remain appropriate for the Group. In summary, the principal risks and uncertainties listed in the Annual Report and 20-F Information 2024 are:

| 1. | Product pipeline risks: failure or delay in the delivery of our pipeline or launch of new medicines; failure to meet regulatory or ethical requirements for medicine development or approval |

| 2. | Commercialisation risks: pricing, affordability, access and competitive pressures; failures or delays in the quality or execution of the Group’s commercial strategies |

| 3. | Supply chain and business-execution risks: failure to maintain supply of compliant, quality medicines; failure in information technology or cybersecurity; failure to collect and manage data or AI in line with legal and regulatory requirements and strategic objectives |

| 4. | Legal,